NCCN Guidelines for Patients® | Follicular Lymphoma Grade 1-2

43 NCCN Guidelines for Patients ® : Follicular Lymphoma, Grade 1–2, 2017 4 Treatment guide Typical type Guide 9. Second-line treatment What are the options? • Drug treatment ◦◦ Bendamustine + rituximab ◦◦ Bendamustine + obinutuzumab ◦◦ RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) ◦◦ CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + obinutuzumab ◦◦ RCVP (rituximab, cyclophosphamide, vincristine, prednisone) ◦◦ CVP (cyclophosphamide, vincristine, prednisone) + obinutuzumab ◦◦ Rituximab ◦◦ Lenalidomide ± rituximab ◦◦ Less harsh chemotherapy ± rituximab ◦◦ Ibritumomab tiuxetan ◦◦ Idelalisib ◦◦ Copanlisib ◦◦ Fludarabine + rituximab ◦◦ RFND (rituximab, fludarabine, mitoxantrone, dexamethasone) ◦◦ DHAP (dexamethasone, cisplatin, cytarabine) ± rituximab ◦◦ ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) ± rituximab ◦◦ GDP [gemcitabine, dexamethasone, (cisplatin or carboplatin)] ± rituximab ◦◦ GemOx (gemcitabine, oxaliplatin) ± rituximab ◦◦ ICE (ifosfamide, carboplatin, etoposide) ± rituximab ◦◦ MINE (mesna, ifosfamide, mitoxantrone, etoposide) ± rituximab ◦◦ Brentuximab vedotin for CD30+ disease ◦◦ CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) ± rituximab ◦◦ CEOP (cyclophosphamide, etoposide, vincristine, prednisone) ± rituximab ◦◦ DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) ± rituximab ◦◦ GDP ± rituximab OR gemcitabine, dexamethasone, carboplatin ± rituximab ◦◦ GemOx ± rituximab • Clinical trial • Local radiation therapy

RkJQdWJsaXNoZXIy MTE3MTE1